2021 Emerging Blood Typing, Grouping and NAT Screening Technologies, and Strategic Profiles of Leading Suppliers

March 2021 | 114 pages | ID: 2ACE6815248EN
Venture Planning Group

Abstracts

This 114-page report provides assessments of such technologies as molecular diagnostics, monoclonal and polyclonal antibodies, immunoassays, microtitration plates, IT, lasers, synthetic red cell substitutes, genetically engineered blood components, blood preservation, autologous blood transfusion/freezing and their potential applications for blood banking.

The report also presents strategic assessments of current and emerging suppliers of blood banking products, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies.

Contains 114 pages

Contents

Current and Emerging Technologies
Molecular Diagnostics
    a. Overview
    b. NAT
Monoclonal and Polyclonal Antibodies
Immunoassays
    a. Technological Principle
    b. Chemiluminescence
    c. Enzyme Immunoassays (EIA)
  Overview
  ELISA
  EMIT
  Electrochemical
    d. Radioimmunoassays (RIA)
    e. Immunoprecipitation
    f. Affinity Chromatography
Microtitration Plates
IT and Automation
Lasers
Robotics
Synthetic Red Cell Substitutes
Genetically Engineered Blood Components
    a. Albumin
    b. Factor VIII
    c. Alpha-2 Antiplasmin
    d. Antithrombin III
    e. Factor IX
    f. Von Willebrand's Factor
    g. Fibrinogen
    h. t-PA
Table of Contents (Continued)
Blood Preservation
Autologous Blood Transfusion/Freezing

COMPETITIVE PROFILES

Abbott
Beckman Coulter/Danaher
Becton Dickinson
Biokit
bioMerieux
Bio-Rad
Diagast
DiaSorin
Fujirebio
Grifols
Hologic
Immucor
LabCorp
Ortho-Clinical Diagnostics
Proteome Sciences
Quest Diagnostics
Quidel
Roche
Siemens Healthineers
Tecan
Thermo Fisher